The global non-opioid pain patches market size was accounted for USD 991.63 million in 2024, grew to USD 1,053.51million in 2025 and is projected to surpass around USD 1,816.48 million by 2034, representing a CAGR of 6.24% between 2025 and 2034. The North America non-opioid pain patches market size is calculated at USD 406.57 million in 2024 and is expected to grow at a CAGR of 6.37% during the forecast year.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Non-Opioid Pain Patches Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Non-Opioid Pain Patches Market, by Patch Type, 2025-2034
8.1.1. Lidocaine Patches
8.1.1.1. Market Revenue and Forecast (2021-2034)
8.1.2. Diclofenac Patches
8.1.2.1. Market Revenue and Forecast (2021-2034)
8.1.3. Methyl Salicylate Patches
8.1.3.1. Market Revenue and Forecast (2021-2034)
8.1.4. Capsaicin Patches
8.1.4.1. Market Revenue and Forecast (2021-2034)
8.1.5. Ketoprofen Patches
8.1.5.1. Market Revenue and Forecast (2021-2034)
8.1.6. Others
8.1.6.1. Market Revenue and Forecast (2021-2034)
9.1. Non-Opioid Pain Patches Market, by Distribution Channel, 2025-2034
9.1.1. Retail Pharmacies
9.1.1.1. Market Revenue and Forecast (2021-2034)
9.1.2. Hospital Pharmacies
9.1.2.1. Market Revenue and Forecast (2021-2034)
9.1.3. Online Pharmacies
9.1.3.1. Market Revenue and Forecast (2021-2034)
9.1.4. Others
9.1.4.1. Market Revenue and Forecast (2021-2034)
10.1. North America
10.1.1. Market Revenue and Forecast, by Patch Type (2021-2034)
10.1.2. Market Revenue and Forecast, by Distribution Channel (2021-2034)
10.1.3. U.S.
10.1.3.1. Market Revenue and Forecast, by Patch Type (2021-2034)
10.1.3.2. Market Revenue and Forecast, by Distribution Channel (2021-2034)
10.1.4. Rest of North America
10.1.4.1. Market Revenue and Forecast, by Patch Type (2021-2034)
10.1.4.2. Market Revenue and Forecast, by Distribution Channel (2021-2034)
10.2. Europe
10.2.1. Market Revenue and Forecast, by Patch Type (2021-2034)
10.2.2. Market Revenue and Forecast, by Distribution Channel (2021-2034)
10.2.3. UK
10.2.3.1. Market Revenue and Forecast, by Patch Type (2021-2034)
10.2.3.2. Market Revenue and Forecast, by Distribution Channel (2021-2034)
10.2.4. Germany
10.2.4.1. Market Revenue and Forecast, by Patch Type (2021-2034)
10.2.4.2. Market Revenue and Forecast, by Distribution Channel (2021-2034)
10.2.5. France
10.2.5.1. Market Revenue and Forecast, by Patch Type (2021-2034)
10.2.5.2. Market Revenue and Forecast, by Distribution Channel (2021-2034)
10.2.6. Rest of Europe
10.2.6.1. Market Revenue and Forecast, by Patch Type (2021-2034)
10.2.6.2. Market Revenue and Forecast, by Distribution Channel (2021-2034)
10.3. APAC
10.3.1. Market Revenue and Forecast, by Patch Type (2021-2034)
10.3.2. Market Revenue and Forecast, by Distribution Channel (2021-2034)
10.3.3. India
10.3.3.1. Market Revenue and Forecast, by Patch Type (2021-2034)
10.3.3.2. Market Revenue and Forecast, by Distribution Channel (2021-2034)
10.3.4. China
10.3.4.1. Market Revenue and Forecast, by Patch Type (2021-2034)
10.3.4.2. Market Revenue and Forecast, by Distribution Channel (2021-2034)
10.3.5. Japan
10.3.5.1. Market Revenue and Forecast, by Patch Type (2021-2034)
10.3.5.2. Market Revenue and Forecast, by Distribution Channel (2021-2034)
10.3.6. Rest of APAC
10.3.6.1. Market Revenue and Forecast, by Patch Type (2021-2034)
10.3.6.2. Market Revenue and Forecast, by Distribution Channel (2021-2034)
10.4. MEA
10.4.1. Market Revenue and Forecast, by Patch Type (2021-2034)
10.4.2. Market Revenue and Forecast, by Distribution Channel (2021-2034)
10.4.3. GCC
10.4.3.1. Market Revenue and Forecast, by Patch Type (2021-2034)
10.4.3.2. Market Revenue and Forecast, by Distribution Channel (2021-2034)
10.4.4. North Africa
10.4.4.1. Market Revenue and Forecast, by Patch Type (2021-2034)
10.4.4.2. Market Revenue and Forecast, by Distribution Channel (2021-2034)
10.4.5. South Africa
10.4.5.1. Market Revenue and Forecast, by Patch Type (2021-2034)
10.4.5.2. Market Revenue and Forecast, by Distribution Channel (2021-2034)
10.4.6. Rest of MEA
10.4.6.1. Market Revenue and Forecast, by Patch Type (2021-2034)
10.4.6.2. Market Revenue and Forecast, by Distribution Channel (2021-2034)
10.5. Latin America
10.5.1. Market Revenue and Forecast, by Patch Type (2021-2034)
10.5.2. Market Revenue and Forecast, by Distribution Channel (2021-2034)
10.5.3. Brazil
10.5.3.1. Market Revenue and Forecast, by Patch Type (2021-2034)
10.5.3.2. Market Revenue and Forecast, by Distribution Channel (2021-2034)
10.5.4. Rest of LATAM
10.5.4.1. Market Revenue and Forecast, by Patch Type (2021-2034)
10.5.4.2. Market Revenue and Forecast, by Distribution Channel (2021-2034)
11.1. Teva Pharmaceutical Industries Ltd.
11.1.1. Company Overview
11.1.2. Product Offerings
11.1.3. Financial Performance
11.1.4. Recent Initiatives
11.2. Teikoku Pharma
11.2.1. Company Overview
11.2.2. Product Offerings
11.2.3. Financial Performance
11.2.4. Recent Initiatives
11.3. Mylan N.V.
11.3.1. Company Overview
11.3.2. Product Offerings
11.3.3. Financial Performance
11.3.4. Recent Initiatives
11.4. IBSA Institut Biochimique SA
11.4.1. Company Overview
11.4.2. Product Offerings
11.4.3. Financial Performance
11.4.4. Recent Initiatives
11.5. Hisamitsu Pharmaceutical Co., Inc.
11.5.1. Company Overview
11.5.2. Product Offerings
11.5.3. Financial Performance
11.5.4. Recent Initiatives
11.6. GSK plc
11.6.1. Company Overview
11.6.2. Product Offerings
11.6.3. Financial Performance
11.6.4. Recent Initiatives
11.7. Endo, Inc.
11.7.1. Company Overview
11.7.2. Product Offerings
11.7.3. Financial Performance
11.7.4. Recent Initiatives
11.8. Alkermes
11.8.1. Company Overview
11.8.2. Product Offerings
11.8.3. Financial Performance
11.8.4. Recent Initiatives
11.9. Acorda Therapeutics, Inc.
11.9.1. Company Overview
11.9.2. Product Offerings
11.9.3. Financial Performance
11.9.4. Recent Initiatives
12.1. Primary Research
12.2. Secondary Research
12.3. Assumptions
13.1. About Us
13.2. Glossary of Terms
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample